Evidence map›Paper›PMID 38307409›Full record

ArticleCancer letters2024

Early elevations of RAS protein level and activity are critical for the development of PDAC in the context of inflammation.

Jianjia Ma, Fanghua Gong, Eunice Kim, James Xianxing Du, Cindy Leung, Qingchun Song, Craig D Logsdon, Yongde Luo, Xiaokun Li, Weiqin Lu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Jianjia MaSchool of Pharmaceutical Sciences & the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.
Fanghua GongSchool of Pharmaceutical Sciences & the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Eunice KimDepartment of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.
James Xianxing DuDepartment of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, 500 W. University Ave, El Paso, TX, 79968, USA.
Cindy LeungDepartment of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.
Qingchun SongDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, 500 W. University Ave, El Paso, TX, 79968, USA.
Craig D LogsdonDepartment of Cancer Biology, MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yongde LuoSchool of Pharmaceutical Sciences & the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA. Electronic address: yongdeluo08@wmu.edu.cn.
Xiaokun LiSchool of Pharmaceutical Sciences & the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address: xiaokunli@wmu.edu.cn.
Weiqin LuDepartment of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, 500 W. University Ave, El Paso, TX, 79968, USA. Electronic address: wlu2@utep.edu.
Wenzhou Medical University · CNThe University of Texas at El Paso · USStony Brook University · USThe University of Texas MD Anderson Cancer Center · US

Funding

Targeting NADPH Oxidase for Pancreatic Cancer Prevention and TherapyR01CA240818 · NCI · UNIVERSITY OF TEXAS EL PASO · PI LU, WEIQIN · 2020 to 2024
$1.7M
Unraveling the Role of NADPH Oxidase in Inflammation-associated Pancreatic DiseasesR01DK123079 · NIDDK · UNIVERSITY OF TEXAS EL PASO · PI LU, WEIQIN · 2020 to 2024
$1.4M
NCI NIH HHS R01 CA240818NIDDK NIH HHS R01 DK123079
6 · The paper itself

Abstract

The KRAS

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsGuanosine TriphosphateInflammationMiceMutationProto-Oncogene Proteins p21(ras)ras ProteinsGuanosine TriphosphateProto-Oncogene Proteins p21(ras)ras ProteinsIKK2InflammationKRAS(G12D)NRASOncogene activationPancreatic cancer

Identifiers

PMID38307409
PMCPMC11032208
OpenAlexW4391451532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.